Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors

A method of treating a subject having a stroke or at risk of developing a stroke by administering a stroke therapeutic agent or stroke therapy, the method comprising:

• a) determining or having determined whether the subject has a 1,4-alpha-glucan-branching enzyme (GBE1) variant nucleic acid molecule, by:
• obtaining or having obtained a biological sample from the subject;
• and
• performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising a GBE1 variant nucleic acid molecule;
• and/or
• b) determining or having determined whether the subject has increased total white matter hyperintensity by imaging the subject;
• and
• administering or continuing to administer the stroke therapeutic agent in an amount that is the same as or less than a standard dosage amount or stroke therapy, and/or a GBE1 inhibitor to a subject that is GBE1 reference;
• or
• administering or continuing to administer the stroke therapeutic agent in an amount that is the same as or less than a standard dosage amount or stroke therapy, and/or a GBE1 inhibitor to a subject that has increased total white matter hyperintensity;
• wherein the presence of a single copy of the GBE1 variant nucleic acid molecule indicates the subject has a decreased risk of developing a stroke compared to a subject that is GBE1 reference.